RxDoctor Payments DataLook up a doctor →

Luis Flores, MD

Hematology & Oncology · San Juan, PRNPI 1285608216

Payments from drug & device makers

$2,252,194in general payments, 2019–2025

Across 1,256 payments — averaging $1793.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.1M
  • AstraZeneca$133K
  • Johnson & Johnson$4K
  • E.r. Squibb & Sons, L.L.C.$3K
  • AbbVie$2K
  • PBG Puerto Rico LLC$1K
  • plus $9K from 42 others

What the payments were for

  • Travel & lodging$7223%
  • Food & beverage$23,11293%
  • Education$1,0704%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,252,194 in reported general payments places this provider in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$92,328
Medicare patients
32
Services billed
3,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide85$1,274,595
RevlimidLenalidomide25$404,090
ImbruvicaIbrutinib12$200,801
SprycelDasatinib11$199,305
XtandiEnzalutamide14$197,970
RetacritEpoetin Alfa-Epbx37$27,943
Anastrozole479$8,566
EliquisApixaban14$8,451
SynthroidLevothyroxine Sodium48$2,536
Hydroxyurea53$2,336
Tamoxifen Citrate55$1,431
Dexamethasone33$1,198
Methylprednisolone96$930
Letrozole29$674
Prednisone56$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$3,883$1,274,59585 claims
Bristol Myers SquibbRevlimid$323$404,09025 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$48$200,80112 claims
E.r. Squibb & Sons, L.L.C.Sprycel$3,215$199,30511 claims
Astellas Pharma US IncXtandi$56$197,97014 claims
PfizerRetacrit, Eliquis$266$36,39351 claims
AbbVieSynthroid$2,119$2,53648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →